Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2015

Supporting Information

Synthesis and structure–activity relationships for cytotoxicity and apoptosis-inducing activity of (+)-halichonine B

Ichiro Hayakawa,**a Tomomi Nakamura,*b Osamu Ohno,*c Kiyotake Suenaga*d and Hideo Kigoshi*b

^a Division of Applied Chemistry, Graduate School of Natural Science and Technology, Okayama University, 3-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan E-mail: ichiro.hayakawa@okayama-u.ac.jp; Fax: +81-86-251-8215

^b Department of Chemistry, Graduate School of Pure and Applied Sciences, University of Tsukuba 1-1-1 Tennodai, Tsukuba 305-8571, Japan E-mail: kigoshi@chem.tsukuba.ac.jp; Fax: +81-29-853-4313

^c Department of Chemistry and Life Science, School of Advanced Engineering, Kogakuin University, 2665-1 Nakano, Hachioji 192-0015, Japan

^d Department of Chemistry, Faculty of Science and Technology, Keio University 3-14-1 Hiyoshi, Yokohama 223-8522, Japan.

Contents:		page	
Table S1	GI ₅₀ values of halichonine B against 39 human cancer cell lines	S2	
Table S2	Results of COMPARE	S3	
Figure S1	igure S1 Relationship between the diamine chain length of halichonine B		
	analogues and cytotoxicity against HL60 cells	S4	
Experimental protocols, characterization data of artificial analogues			
¹ H and ¹³ C NMR spectra of newly synthesized compounds			

Table S1 GI₅₀ values of halichonine B (2) against 39 human cancer cell lines

		$GI_{50}^{a,b}\left(\mu\mathrm{M}\right)$	
Type of cancer	Cell line	halichonine B free amine	halichonine B HCl salt
Breast	HBC-4	2.0	1.7
	BSY-1	2.0	1.6
	HBC-5	2.9	1.9
	MCF-7	3.4	1.9
	MDA-MB-231	12	1.8
Central nervous	U251	3.6	1.7
	SF-268	13	1.7
	SF-295	8.8	1.8
	SF-539	2.0	1.9
	SNB-75	16	1.9
	SNB-78	17	1.8
Colon	HCC2998	1.7	1.2
	KM-12	7.3	1.9
	HT-29	3.4	1.7
	HCT-15	11	1.8
	HCT-116	6.0	1.8
Lung	NCI-H23	13	1.8
8	NCI-H226	14	2.0
	NCI-H522	2.5	1.7
	NCI-H460	3.5	1.8
	A549	16	1.9
	DMS273	4.7	1.9
	DMS114	1.9	1.6
Melanoma	LOX-IMVI	8.6	1.9
Ovary	OVCAR-3	13	1.7
o vary	OVCAR-4	11	1.8
	OVCAR-5	3.5	1.7
	OVCAR-8	11	2.0
	SK-OV-3	18	2.1
Kidney	RXF-631L	13	1.8
Ridicy	ACHN	17	1.8
Stomach	St-4	16	1.8
Stomach	MKN1	11	1.6
	MKN7	3.1	2.0
	MKN28	4.6	1.7
	MKN45	10	1.6
		2.3	1.7
Prostate	MKN74 DU-145	2.3 14	1.7
Flostate	PC-3	16	1.9
MC MID ^c			
$MG-MID^c$ Delta ^d		-5.17	-5.75 0.16
Della Danas ^e		0.59	0.16
Range ^e		1.02	0.24


 ^a Concentrations for the inhibition of cell growth at 50% relative to control.
 ^b Cell growth was determined according to the sulforhodamine B assay.
 ^c Mean GI₅₀ value in all of the cell lines tested.
 ^d Difference in the GI₅₀ value between the most-sensitive cells and the MG-MID value.

^e Difference in the log GI₅₀ value between the most- and least-sensitive cells.

Table S2 Results of COMPARE

sample	known compounds	r (correlation coefficient)	molecular targets/drug type
halichonine B free amine	Tamoxifen citrate	0.724	Selective Estrogen Receptor Modulators (SERM), anticancer drugs, Protein Kinase C estrogen receptor
halichonine B	Toremifene citrate	0.494	Selective Estrogen Receptor Modulators (SERM), anticancer drugs/estrogen antagonist
HCl salt	Tamoxifen citrate	0.48	Selective Estrogen Receptor Modulators (SERM), anticancer drugs, Protein Kinase C estrogen receptor

Figure S1 Relationship between the diamine chain length of halichonine B analogues and cytotoxicity against HL60 cells



Experimental protocols and characterization data of artificial analogues

General procedure for the preparation of alcohol S2a-d

$$\begin{array}{c} \text{1)} & \text{CHO} \\ \textbf{16} \\ \text{MS3A, CH_2Cl_2, rt} \\ \text{then $NaBH_4$, $MeOH$} \\ \textbf{2)} & \text{Boc}_2O, $Et_3N, $THF, rt} \\ \textbf{S1a n} = 2 \\ \textbf{S1b n} = 3 \\ \textbf{S1c n} = 6 \\ \textbf{S1d n} = 8 \\ \textbf{S2d n} = 8$$

To a stirred solution of amino alcohol **S1a–d** in CH₂Cl₂ (ca. 0.1 M) containing molecular sieves 3Å was added 3-methyl-2-butenal (**16**) (1.1 equiv.) at room temperature, and the mixture was stirred at room temperature for ca. 20 h. The mixture was filtered through a pad of Celite, and the residue was washed with CH₂Cl₂. Concentration of the filtrate and washings afforded the crude imine intermediate.

To a stirred solution of the crude imine intermediate in MeOH (ca. 1.0 M) was added NaBH₄ (2.0 equiv.) at 0 °C. After being stirred at room temperature for 30 min, the reaction mixture was diluted with H_2O and extracted with CH_2Cl_2 (× 5). The combined extracts were washed with brine, dried

over Na₂SO₄, and filtered. Removal of the solvent afforded the crude amine, which was used for the next reaction without further purification.

To a stirred solution of the crude amine in THF (ca. 0.2 M) were added Boc₂O (1.2 equiv.) and Et₃N (2.0 equiv.) at 0 °C. After being stirred at room temperature for ca. 1 h, the reaction mixture was diluted with saturated aqueous NH₄Cl and extracted with EtOAc (× 3). The combined extracts were washed with brine, dried over MgSO₄, filtered, and concentrated. The crude product was purified by column chromatography on silica gel (n-hexane–Et₂O 5 : 1 \rightarrow n-hexane–EtOAc 1 : 1 for S2a; n-hexane–EtOAc for S2b–S2d) to give alcohol S2a–d.

tert-butyl (2-hydroxyethyl)(3-methylbut-2-en-1-yl)carbamate [**S2a** (n = 2)]. Colorless oil (168 mg, 50% yield in 2 steps): R_f = 0.51 (n-hexane–EtOAc 2 : 1); IR (CHCl₃) 3429, 3010, 2980, 2934, 1665, 1455, 1415, 1252, 1166, 1050, 869 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 5.14 (m, 1H), 3.93–3.77 (br m, 2H), 3.74–3.63 (m, 2H), 3.42–3.20 (br m, 3H), 1.71 (s, 3H), 1.64 (s, 3H), 1.44 (s, 9H); ¹³C NMR (150 MHz, CDCl₃) δ 157.0, 135.4, 120.6, 80.0, 62.5, 49.6, 46.2, 28.4 (3C), 25.7, 17.8; HRMS (ESI) m/z 252.1568, calcd for C₁₂H₂₃NNaO₃ [M+Na]⁺ 252.1576.

tert-butyl (3-hydroxypropyl)(3-methylbut-2-en-1-yl)carbamate [**S2b** (n = 3)]. Colorless oil (378 mg, quant. in 2 steps): R_f = 0.54 (n-hexane–EtOAc 1 : 1); IR (CHCl₃) 3411, 3009, 2980, 2937, 1661, 1478, 1420, 1253, 1164, 1076, 883 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 5.13 (m, 1H), 3.97–3.68 (br m, 3H), 3.62–3.44 (br m, 2H), 3.39–3.20 (br m, 2H), 1.79–1.37 (m, 2H), 1.71 (s, 3H), 1.64 (s, 3H), 1.43 (s, 9H); ¹³C NMR (150 MHz, CDCl₃) δ 157.0, 134.8, 120.7, 79.9, 58.4, 44.7, 42.1, 30.5, 28.4 (3C), 25.6, 17.7; HRMS (ESI) m/z 266.1746, calcd for C₁₃H₂₅NNaO₃ [M+Na]+ 266.1732.

tert-butyl (6-hydroxyhexyl)(3-methylbut-2-en-1-yl)carbamate [**S2c** (n = 6)]. Colorless oil (192 mg, 82% yield in 2 steps): R_f = 0.55 (n-hexane–EtOAc 2 : 1); IR (CHCl₃) 3626, 3449, 3008, 2978, 2935, 1668, 1454, 1419, 1251, 1168, 1077, 882 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 5.13 (m, 1H), 3.88–3.70 (br m, 2H), 3.62 (t, J = 6.5 Hz, 2H), 3.24–3.04 (br m, 2H), 1.71 (s, 3H), 1.65 (s, 3H), 1.61–1.23 (m, 8H), 1.44 (s, 9H). A signal due to one proton (OH) was not observed; ¹³C NMR (150 MHz, CDCl₃) δ 155.7, 134.7, 121.2, 79.1, 62.7, 46.0, 44.4, 32.7, 28.5 (3C), 28.2, 26.5, 25.6, 25.3, 17.7; HRMS (ESI) m/z 308.2201, calcd for C₁₆H₃₁NNaO₃ [M+Na]⁺ 308.2202.

tert-butyl (8-hydroxyoctyl)(3-methylbut-2-en-1-yl)carbamate [**S2d** (n = 8)]. Colorless oil (202 mg, 78% yield in 2 steps): R_f = 0.42 (n-hexane–EtOAc 2 : 1); IR (CHCl₃) 3628, 3451, 3009, 2978, 2932, 1669, 1455, 1419, 1252, 1168, 1050, 880 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 5.14 (m, 1H), 3.89–3.69 (br m, 2H), 3.63 (t, J = 6.6 Hz, 2H), 3.20–3.01 (br m, 2H), 1.71 (s, 3H), 1.65 (s, 3H), 1.59–1.18 (m, 12H), 1.44 (s, 9H). A signal due to one proton (OH) was not observed; ¹³C NMR (150

MHz, CDCl₃) δ 155.6, 134.0, 121.2, 79.0, 62.8, 46.2, 44.1, 32.7, 29.3 (2C), 28.5 (3C), 28.2, 26.8, 25.6 (2C), 17.7; HRMS (ESI) *m/z* 336.2539, calcd for C₁₈H₃₅NNaO₃ [M+Na]⁺ 336.2515.

General procedure for the preparation of amine S4a-d

To a stirred solution of Ns-amide **5**, alcohol **S2a-d** (3.0 equiv.), and PPh₃ (3.0 equiv.) in benzene (0.10 M) was added DIAD (3.0 equiv.) at room temperature. The mixture was stirred at reflux for ca. 15 h. Removal of the solvent afforded crude product, which was purified by column chromatography on silica gel to give coupling compound **S3a-d** (containing impurities). The coupling compound **S3a-d** was used for the next reaction without further purification.

To a stirred solution of coupling compounds S3a-d (containing impurities) and Cs_2CO_3 (1.7 equiv.) in MeCN (0.1 M) was added PhSH (1.4 equiv.) at 0 °C. After being stirred at room temperature for ca. 15 h, the mixture was filtered through a pad of Celite, and the residue was washed with EtOAc. Concentration of the filtrate and washings afforded the crude product, which was purified by column chromatography on Al_2O_3 (n-hexane– Et_2O) to give amine S4a-d.

tert-butyl (3-methylbut-2-en-1-yl)(2-((((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methyl)amino)ethyl)carbamate [**S4a** (n = 2)]. Yellow oil (18.8 mg, 30% yield in 2 steps): R_f = 0.58 (CHCl₃–MeOH 8 : 1); [α]_D²⁴ +2.8 (c 0.24, CHCl₃); IR (CHCl₃) 3360, 3020, 2927, 2850, 1682, 1456, 1416, 1366, 1251, 1166, 1138, 884 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 5.43 (m, 1H), 5.15 (m, 1H), 3.92–3.72 (br m, 2H), 3.38–3.14 (br m, 2H), 2.82–2.62 (m, 3H), 2.50 (m, 1H), 2.01–1.79 (m, 3H), 1.78–1.36 (m, 4H), 1.71 (s, 6H), 1.65 (s, 3H), 1.44 (s, 9H), 1.23–1.12 (m, 2H), 1.05 (ddd, J = 13.1, 13.1, 3.6 Hz, 1H), 0.87 (s, 3H), 0.85 (s, 3H), 0.76 (s, 3H). A signal due to one proton (NH) was not observed; ¹³C NMR (150 MHz, CDCl₃) δ 155.7, 134.8, 134.3, 122.9, 121.1, 79.3, 55.5, 50.0, 48.6, 48.2, 46.5, 45.2, 42.2, 39.4, 36.2, 33.2, 32.9, 28.5 (3C), 25.7, 23.7, 21.9 (2C), 18.8, 17.8, 14.1; HRMS (ESI) m/z 433.3796, calcd for C₂₇H₄₉N₂O₂ [M+H]⁺ 433.3789.

tert-butyl (3-methylbut-2-en-1-yl)(3-((((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methyl)amino)propyl)carbamate [**S4b** (n = 3)]. Yellow oil (21.5 mg, 63% yield in 2 steps): R_f = 0.47 (CHCl₃-MeOH 8 : 1); [α]_D²⁴ +3.3 (c 0.57, CHCl₃); IR (CHCl₃) 3330,

3009, 2927, 2856, 1681, 1456, 1419, 1366, 1251, 1167, 1137, 869 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 5.42 (m, 1H), 5.13 (m, 1H), 3.88–3.68 (br m, 2H), 3.29–3.19 (br m, 2H), 2.67 (dd, J = 12.2, 1.5 Hz, 1H), 2.61 (ddd, J = 11.7, 7.1, 7.1 Hz, 1H), 2.56–2.41 (m, 2H), 2.00–1.22 (m, 9H), 1.72 (s, 3H), 1.70 (s, 3H), 1.64 (s, 3H), 1.44 (s, 9H), 1.20–1.11 (m, 2H), 1.06 (ddd, J = 13.1, 13.1, 3.4 Hz, 1H), 0.86 (s, 3H), 0.84 (s, 3H), 0.74 (s, 3H). A signal due to one proton (NH) was not observed; ¹³C NMR (150 MHz, CDCl₃) δ 155.6, 134.9, 134.3, 122.8, 121.1, 79.2, 55.2, 50.0, 48.2, 47.6, 44.5, 44.2, 42.2, 39.4, 36.2, 33.2, 32.9, 29.0, 28.5 (3C), 25.7, 23.7, 21.9 (2C), 18.8, 17.8, 14.0; HRMS (ESI) m/z 447.3964, calcd for $C_{28}H_{51}N_2O_2$ [M+H]⁺ 447.3945.

tert-butyl (3-methylbut-2-en-1-yl)(6-((((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methyl)amino)hexyl)carbamate [**S4c** (n = 6)]. Yellow oil (19.6 mg, 53% yield in 2 steps): R_f = 0.50 (CHCl₃–MeOH 8 : 1); [α]_D²⁴ +1.5 (c 0.13, CHCl₃); IR (CHCl₃) 3336, 3018, 2930, 2855, 1681, 1456, 1419, 1366, 1251, 1168, 1134, 880 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 5.42 (m, 1H), 5.13 (m, 1H), 3.85–3.70 (br m, 2H), 3.19–3.02 (br m, 2H), 2.69 (dd, J = 12.2, 1.6 Hz, 1H), 2.60 (ddd, J = 11.4, 7.2, 7.2 Hz, 1H), 2.50 (ddd, J = 11.4, 7.2, 7.2 Hz, 1H), 2.45 (dd, J = 12.2, 7.3 Hz, 1H), 2.00–1.12 (m, 17H), 1.71 (s, 3H), 1.71 (s, 3H), 1.64 (s, 3H), 1.44 (s, 9H), 1.07 (ddd, J = 13.2, 13.2, 3.7 Hz, 1H), 0.87 (s, 3H), 0.84 (s, 3H), 0.75 (s, 3H). A signal due to one proton (NH) was not observed; ¹³C NMR (150 MHz, CDCl₃) δ 155.6, 134.8, 134.3, 122.9, 121.2, 79.0, 55.3, 50.2, 50.0, 48.3, 46.2, 44.6, 42.2, 39.3, 36.2, 33.2, 33.0, 30.1, 28.5 (3C), 28.4, 27.2, 26.9, 25.7, 23.7, 21.9 (2C), 18.8, 17.8, 14.0; HRMS (ESI) m/z 489.4430, calcd for C₃₁H₅₇N₂O₂ [M+H]⁺ 489.4415.

tert-butyl (3-methylbut-2-en-1-yl)(8-((((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methyl)amino)octyl)carbamate [**S4d** (n = 8)]. Yellow oil (38.9 mg, 67% yield in 2 steps): R_f = 0.53 (CHCl₃-MeOH 8 : 1); [α]_D²⁴ +1.5 (c 0.13, CHCl₃); IR (CHCl₃) 3355, 3018, 2929, 2856, 1669, 1457, 1419, 1366, 1251, 1168, 881 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 5.42 (m, 1H), 5.13 (m, 1H), 3.87–3.68 (br m, 2H), 3.20–3.01 (br m, 2H), 2.69 (dd, J = 12.1, 1.2 Hz, 1H), 2.60 (ddd, J = 11.4, 7.2, 7.2 Hz, 1H), 2.50 (ddd, J = 11.4, 7.2, 7.2 Hz, 1H), 2.45 (dd, J = 12.1, 7.4 Hz, 1H), 2.00–1.79 (m, 3H), 1.77–1.12 (m, 18H), 1.72 (s, 3H), 1.70 (s, 3H), 1.64 (s, 3H), 1.44 (s, 9H), 1.07 (ddd, J = 13.1, 13.1, 3.6 Hz, 1H), 0.86 (s, 3H), 0.84 (s, 3H), 0.75 (s, 3H). A signal due to one proton (NH) was not observed; ¹³C NMR (150 MHz, CDCl₃) δ 155.6, 134.7, 134.3, 122.9, 121.2, 79.0, 55.3, 50.3, 50.0, 48.2, 46.2, 44.6, 42.2, 39.3, 36.2, 33.2, 33.0, 30.0, 29.5, 29.3, 28.5 (3C), 28.2, 27.4, 26.9, 25.7, 23.7, 21.9 (2C), 18.8, 17.8, 14.0; HRMS (ESI) m/z 517.4735, calcd for $C_{33}H_{61}N_2O_2$ [M+H]⁺ 517.4728

General procedure for the preparation of S5a-d

To a stirred solution of amine **S4a–d** in MeCN (0.2 M) were added *i*-Pr₂NEt (1.0 equiv.) and prenyl bromide (2.4 equiv.) at 0 °C. After being stirred at room temperature for ca. 1.5–20 h, the reaction mixture was diluted with H₂O and extracted with EtOAc (× 3). The combined extracts were washed with brine, dried over Na₂SO₄, filtered, and concentrated. The crude product was purified by column chromatography on Al₂O₃ (n-hexane–Et₂O for **S5a**, **S5c**, and **S5d**; n-hexane–Et₂OAc 9 : 1 for **S5b**) to give compound **S5a–d**.

tert-butyl (3-methylbut-2-en-1-yl)(2-((3-methylbut-2-en-1-yl))(((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methyl)amino)ethyl)carbamate [**S5a** (n = 2)]. Yellow oil (9.3 mg, 74% yield): R_f = 0.43 (n-hexane–Et₂O 4 : 1); [α]_D²⁴ +26.6 (c 0.45, CHCl₃); IR (CHCl₃) 2926, 2851, 1680, 1457, 1416, 1366, 1251, 1169, 880 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 5.38 (m, 1H), 5.24 (m, 1H), 5.14 (m, 1H), 3.91–3.72 (br m, 2H), 3.33–3.06 (br m, 3H), 2.90 (br m, 1H), 2.70 (br m, 1H), 2.40–2.21 (m, 3H), 2.06–1.90 (br m, 2H), 1.88–1.32 (m, 5H), 1.74 (s, 3H), 1.72 (s, 3H), 1.71 (s, 3H), 1.66 (s, 3H), 1.62 (s, 3H), 1.45 (s, 9H), 1.23–1.10 (m, 2H), 1.01 (ddd, J = 13.1, 13.1, 3.3 Hz, 1H), 0.87 (s, 3H), 0.84 (s, 3H), 0.72 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 155.6, 135.8, 134.9, 134.2, 122.0, 121.9, 121.2, 79.1, 53.9, 52.0, 51.8 (2C), 50.2, 45.6, 44.8, 42.3, 39.2, 36.1, 33.3, 33.0, 28.5 (3C), 25.9, 25.8, 23.7, 22.4, 22.0, 18.8, 18.0, 17.8, 13.7; HRMS (ESI) m/z 501.4401, calcd for C₃₂H₅₇N₂O₂ [M+H]⁺ 501.4415.

tert-butyl (3-methylbut-2-en-1-yl)(3-((3-methylbut-2-en-1-yl)(((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methyl)amino)propyl)carbamate [**S5b** (n = 3)]. Yellow oil (8.0 mg, 53% yield): R_f = 0.61 (n-hexane–Et₂O 2 : 1); [α]_D²⁴ +42.2 (c 0.65, CHCl₃); IR (CHCl₃) 2926, 2878, 1669, 1445, 1419, 1366, 1251, 1167, 869 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 5.38 (m, 1H), 5.22 (m, 1H), 5.14 (m, 1H), 3.88–3.69 (br m, 2H), 3.21–2.98 (br m, 3H), 2.87 (m, 1H), 2.49 (br m, 1H), 2.33–2.14 (m, 3H), 2.03–1.92 (br m, 2H), 1.87–1.36 (m, 7H), 1.74 (s, 3H), 1.71 (s, 6H), 1.65 (s, 3H), 1.62 (s, 3H), 1.44 (s, 9H), 1.23–1.11 (m, 2H), 0.99 (ddd, J = 13.1, 13.1, 3.3 Hz, 1H), 0.87 (s, 3H), 0.85 (s, 3H), 0.72 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 155.6, 136.0, 134.7, 134.0, 121.9, 121.8, 121.3, 79.0, 53.8, 51.6, 51.1, 51.0, 50.2, 45.2, 44.3, 42.3, 39.2, 36.1, 33.3, 33.0, 28.5

(3C), 25.9, 25.7 (2C), 23.7, 22.4, 22.0, 18.8, 17.9, 17.8, 13.7; HRMS (ESI) m/z 515.4544, calcd for $C_{33}H_{59}N_2O_2[M+H]^+$ 515.4571.

tert-butyl (3-methylbut-2-en-1-yl)(6-((3-methylbut-2-en-1-yl))(((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methyl)amino)hexyl)carbamate [**S5c** (n = 6)]. Yellow oil (12.1 mg, quant): R_f = 0.63 (n-hexane–Et₂O 4 : 1); [α]_D²⁴ +36.6 (c 0.41, CHCl₃); IR (CHCl₃) 2929, 2857, 1669, 1454, 1419, 1366, 1251, 1168, 879 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 5.38 (m, 1H), 5.23 (m, 1H), 5.14 (m, 1H), 3.87–3.69 (br m, 2H), 3.19–3.03 (br m, 3H), 2.83 (dd, J = 14.2, 7.6 Hz, 1H), 2.48 (m, 1H), 2.32–2.24 (m, 2H), 2.18 (m, 1H), 2.05–1.92 (br m, 2H), 1.87–1.35 (m, 9H), 1.75 (s, 3H), 1.71 (s, 3H), 1.65 (s, 3H), 1.62 (s, 3H), 1.45 (s, 9H), 1.32–1.13 (m, 6H), 0.99 (ddd, J = 13.1, 13.1, 3.3 Hz, 1H), 0.87 (s, 3H), 0.85 (s, 3H), 0.73 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 155.6, 136.2, 134.6, 133.7, 122.2, 121.9, 121.2, 79.0, 53.8, 53.6, 51.5, 51.2, 50.3, 46.2, 44.4, 42.3, 39.2, 36.2, 33.3, 33.0, 28.5 (3C), 28.4, 27.5, 27.0, 26.9, 25.9, 25.7, 23.7, 22.4, 22.0, 18.8, 17.9, 17.8, 13.7; HRMS (ESI) m/z 557.5031, calcd for C₃₆H₆₅N₂O₂ [M+H]⁺ 557.5041.

tert-butyl (3-methylbut-2-en-1-yl)(8-((3-methylbut-2-en-1-yl)(((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methyl)amino)octyl)carbamate [**S5d** (n = 8)]. Yellow oil (21.7 mg, 79% yield): $R_f = 0.49$ (n-hexane—Et₂O 4 : 1); [α]_D²⁴ +40.7 (c 0.44, CHCl₃); IR (CHCl₃) 2929, 2856, 1668, 1455, 1419, 1366, 1251, 1167, 1135, 881 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 5.38 (m, 1H), 5.23 (m, 1H), 5.14 (m, 1H), 3.87–3.69 (br m, 2H), 3.19–3.02 (br m, 3H), 2.84 (dd, J = 14.1, 7.6 Hz, 1H), 2.48 (m, 1H), 2.33–2.23 (m, 2H), 2.17 (m, 1H), 2.05–1.91 (br m, 2H), 1.88–1.35 (m, 9H), 1.75 (s, 3H), 1.71 (s, 6H), 1.65 (s, 3H), 1.62 (s, 3H), 1.45 (s, 9H), 1.32–1.11 (m, 10H), 0.98 (ddd, J = 13.1, 13.1, 3.3 Hz, 1H), 0.87 (s, 3H), 0.85 (s, 3H), 0.73 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 155.6, 136.3, 134.7, 133.6, 122.2, 121.8, 121.2, 79.0, 53.8, 53.6, 51.6, 51.2, 50.3, 46.2, 44.0, 42.3, 39.2, 36.2, 33.3, 33.0, 29.7, 29.4, 28.5 (3C), 28.3, 27.7, 26.9, 26.8, 25.9, 25.7, 23.7, 22.4, 22.0, 18.9, 17.9, 17.8, 13.7.; HRMS (ESI) m/z 585.5359, calcd for C₃₈H₆₉N₂O₂ [M+H]⁺ 585.5354.

General procedure for the preparation of natural product-type analogues 21–24

The compound S5a-d was treated with 4.0 M HCl/MeOH at 0 °C. After being stirred at room temperature for ca. 17 h, the reaction mixture was concentrated to afford 21–24 HCl salt. The 21–24 HCl salt was purified by column chromatography on Al_2O_3 (CHCl₃–MeOH for 21, 23, and 24; n-hexane–EtOAc 5 : 1 for 22) to give natural product-type analogues (free amine) 21–24.

 N^1 , N^2 -bis(3-methylbut-2-en-1-yl)- N^1 -(((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methyl)ethane-1,2-diamine [**21** (n = 2)]. Yellow oil (5.3 mg, quant.): R_f = 0.48 (CHCl₃-MeOH 9 : 1); $[\alpha]_D^{24}$ +26.6 (c 0.12, CHCl₃); IR (CHCl₃) 3307, 2960, 2925, 2850, 1675, 1456, 1378, 1224, 1093, 987 cm⁻¹; ¹H NMR (600 MHz, CD₃OD) δ 5.40 (m, 1H), 5.30–5.21 (m, 2H), 3.24–3.18 (m, 2H), 3.15 (dd, J = 14.2, 6.1 Hz, 1H), 2.92 (dd, J = 14.2, 7.8 Hz, 1H), 2.79–2.57 (m, 3H), 2.43–2.50 (m, 3H), 2.06–1.82 (br m, 4H), 1.74 (s, 6H), 1.73 (s, 3H), 1.68 (s, 3H), 1.66 (s, 3H), 1.58 (m, 1H), 1.49–1.39 (m, 2H), 1.27–1.17 (m, 2H), 1.10 (ddd, J = 13.2, 13.2, 3.4 Hz, 1H), 0.90 (s, 3H), 0.87 (s, 3H), 0.77 (s, 3H). A signal due to one proton (NH) was not observed; ¹³C NMR (150 MHz, CD₃OD) δ 136.8, 136.4, 135.9, 123.4, 122.6, 122.5, 55.3, 53.5, 52.8, 52.7, 51.6, 47.5, 47.1, 43.4, 40.4, 37.4, 34.0, 33.8, 26.0, 25.9, 24.8, 23.0, 22.4, 19.8, 18.0 (2C), 14.2; HRMS (ESI) m/z 401.3860, calcd for C₂₇H₄₉N₂ [M+H]⁺ 401.3890.

 N^1 , N^3 -bis(3-methylbut-2-en-1-yl)- N^1 -(((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methyl)propane-1,3-diamine [**22** (n = 3)]. Yellow oil (1.9 mg, 40% yield): R_f = 0.24 (CHCl₃-MeOH 9 : 1); [α]_D²⁴ +40.5 (c 0.19, CHCl₃); IR (CHCl₃) 3388, 2960, 2928, 2855, 1675, 1456, 1378, 1261, 1095, 1006 cm⁻¹; ¹H NMR (600 MHz, CD₃OD) δ 5.39 (m, 1H), 5.30–5.19 (m, 2H), 3.18 (d, J = 6.9 Hz, 2H), 3.13 (m, 1H), 2.94 (dd, J = 14.2, 7.9 Hz, 1H), 2.68–2.55 (m, 3H), 2.35–2.25 (m, 3H), 2.08–1.92 (br m, 4H), 1.78–1.38 (m, 5H), 1.75 (s, 3H), 1.74 (s, 6H), 1.66 (s, 3H), 1.58 (s, 3H), 1.25–1.15 (m, 2H), 1.06 (ddd, J = 13.1, 13.1, 3.3 Hz, 1H), 0.90 (s, 3H), 0.87 (s, 3H), 0.77 (s, 3H). A signal due to one proton (NH) was not observed; ¹³C NMR (150 MHz, CD₃OD) δ 136.6, 135.7, 135.6, 123.3, 123.2, 122.7, 55.0, 53.2, 53.0, 52.3, 51.7, 49.6, 47.6, 43.5, 40.5, 37.4, 34.0, 33.8, 26.1, 25.9, 24.8, 22.9 (2C), 22.4, 19.9, 18.1, 18.0, 14.1; HRMS (ESI) m/z 415.4032, calcd for C₂₈H₅₁N₂ [M+H]⁺ 415.4047.

 N^1 , N^6 -bis(3-methylbut-2-en-1-yl)- N^1 -(((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methyl)hexane-1,6-diamine [**23** (n = 6)]. Yellow oil (4.1 mg, quant.): R_f = 0.20 (CHCl₃-MeOH 9 : 1); $[\alpha]_D^{24}$ –39.7 (c 0.33, CHCl₃); IR (CHCl₃) 3300, 2929, 2856, 1666, 1456, 1378, 1266, 1096, 986 cm⁻¹; ¹H NMR (400 MHz, CD₃OD) δ 5.37 (m, 1H), 5.31–5.21 (m, 2H), 3.20 (d, J = 7.0 Hz, 2H), 3.13 (dd, J = 13.9, 5.7 Hz, 1H), 2.88 (dd, J = 13.9, 7.6 Hz, 1H), 2.61–2.47 (m, 3H), 2.38–2.17 (m, 3H), 2.17–1.80 (m, 4H), 1.75 (s, 3H), 1.74 (s, 3H), 1.72 (s, 3H), 1.67 (s, 3H), 1.65 (s, 3H), 1.62–1.14 (m, 13H), 1.03 (ddd, J = 13.1, 13.1, 3.4 Hz, 1H), 0.90 (s, 3H), 0.87 (s,

3H), 0.76 (s, 3H). A signal due to one proton (NH) was not observed; 13 C NMR (100 MHz, CD₃OD) δ 136.9, 136.2, 135.1, 123.1, 123.0, 122.8, 54.9, 54.6, 53.0, 52.4, 51.7, 49.9, 47.6, 43.5, 40.6, 37.4, 34.0, 33.8, 30.3, 28.6, 28.4, 27.8, 26.1, 25.9, 24.8, 22.9, 22.4, 19.9, 18.0 (2C), 14.1; HRMS (ESI) m/z 457.4521, calcd for $C_{31}H_{57}N_{2}$ [M+H]⁺ 457.4516.

 N^1 , N^8 -bis(3-methylbut-2-en-1-yl)- N^1 -(((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methyl)octane-1,8-diamine [**24** (n = 8)]. Yellow oil (10.2 mg, 76% yield): R_f = 0.36 (CHCl₃-MeOH 9 : 1); [α]_D²⁴ +41.1 (c 0.84, CHCl₃); IR (CHCl₃) 3305, 2929, 2855, 1670, 1456, 1381, 1271, 1095, 987 cm⁻¹; ¹H NMR (400 MHz, CD₃OD) δ 5.37 (m, 1H), 5.30–5.20 (m, 2H), 3.19 (d, J = 6.8 Hz, 2H), 3.13 (dd, J = 14.0, 6.0 Hz, 1H), 2.88 (dd, J = 14.0, 7.5 Hz, 1H), 2.62–2.48 (m, 3H), 2.40–2.18 (m, 3H), 2.11–1.81 (m, 4H), 1.75 (s, 3H), 1.74 (s, 3H), 1.72 (s, 3H), 1.67 (s, 3H), 1.65 (s, 3H), 1.62–1.16 (m, 17H), 1.04 (ddd, J = 13.1, 13.1, 3.4 Hz, 1H), 0.90 (s, 3H), 0.87 (s, 3H), 0.76 (s, 3H). A signal due to one proton (NH) was not observed; ¹³C NMR (100 MHz, CD₃OD) δ 136.9, 136.1, 135.1, 123.2, 123.0, 122.9, 54.9, 54.6, 53.1, 52.4, 51.7, 50.0, 47.6, 43.5, 40.6, 37.4, 34.0, 33.9, 30.6 (2C), 30.4, 28.6, 28.4, 27.8, 26.1, 25.9, 24.8, 22.9, 22.4, 19.9, 18.0 (2C), 14.1; HRMS (ESI) m/z 485.4820, calcd for C₃₃H₆₁N₂ [M+H]⁺ 485.4829.

General procedure for the preparation of diamine-type analogues 25–28

The amine **S4a-d** was treated with 4.0 M HCl/MeOH at 0 °C. After being stirred at room temperature for ca. 2.5–17 h, the reaction mixture was concentrated to afford diamine-type analogues **25–28**.


 N^1 -(3-methylbut-2-en-1-yl)- N^2 -(((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methyl)ethane-1,2-diamine [**25** (n = 2)]. Yellow oil (4.6 mg, 95% yield): $R_f = 0.28$ (CHCl₃-MeOH 4 : 1); $[\alpha]_D^{24}$ -10.8 (c 0.43, CHCl₃); IR (CHCl₃) 3372, 2965, 2855, 2777, 2450, 1589, 1442, 1389, 1236, 983 cm⁻¹; ¹H NMR (400 MHz, CD₃OD) δ 5.60 (m, 1H), 5.35 (t, J = 7.5 Hz, 1H), 3.73 (d, J = 7.5 Hz, 2H), 3.58–3.41 (m, 4H), 3.28–3.26 (m, 2H), 2.31–1.20 (m, 7H), 1.85 (s, 6H), 1.81 (s, 3H), 1,36–1.20 (m, 3H), 0.93 (s, 3H), 0.90 (s, 3H), 0.83 (s, 3H). Signals due to two proton (NH) were not observed; ¹³C NMR (100 MHz, CD₃OD) δ 145.2, 131.5, 126.3, 114.5,

53.8, 50.9, 48.7, 46.7, 46.1, 43.5, 43.0, 40.1, 37.7, 33.9, 33.5, 26.0, 24.7, 22.1, 22.0, 19.6, 18.4, 14.0; HRMS (ESI) m/z 333.3278, calcd for $C_{22}H_{41}N_2$ [M+H]⁺ 333.3264.


 N^1 -(3-methylbut-2-en-1-yl)- N^3 -(((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methyl)propane-1,3-diamine [**26** (n = 3)]. Yellow solid (10.8 mg, 91% yield): R_f = 0.42 (CHCl₃–MeOH 4 : 1); [α]_D²⁴ –10.7 (c 0.88, CHCl₃); IR (CHCl₃) 3393, 3040, 2964, 2763, 2690, 1456, 1240, 1167 cm⁻¹; ¹H NMR (400 MHz, CD₃OD) δ 5.59 (m, 1H), 5.34 (m, 1H), 3.68 (d, J = 7.2 Hz, 2H), 3.28–3.05 (m, 6H), 2.30–1.41 (m, 9H), 1.84 (s, 6H), 1.80 (s, 3H), 1,37–1.17 (m, 3H), 0.92 (s, 3H), 0.89 (s, 3H), 0.83 (s, 3H). Signals due to two proton (NH) were not observed; ¹³C NMR (100 MHz, CD₃OD) δ 144.4, 131.6, 126.2, 114.9, 53.7, 50.9, 48.2, 47.3, 46.5, 45.0, 43.0, 40.0, 37.7, 33.9, 33.5, 26.0, 24.7, 24.0, 22.1, 21.9, 19.6, 18.4, 14.0; HRMS (ESI) m/z 347.3423, calcd for C₂₃H₄₃N₂ [M+H]⁺ 347.3421.

 N^1 -(3-methylbut-2-en-1-yl)- N^6 -(((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methyl)hexane-1,6-diamine [**27** (n = 6)]. Yellow oil (5.0 mg, 95% yield): $R_f = 0.57$ (CHCl₃-MeOH 4 : 1); $[\alpha]_D^{24}$ -7.6 (c 0.41, CHCl₃); IR (CHCl₃) 3409, 2964, 2861, 2774, 1592, 1457, 1385, 1241, 984 cm⁻¹; ¹H NMR (600 MHz, CD₃OD) δ 5.59 (m, 1H), 5.31 (m, 1H), 3.63 (d, J = 6.4 Hz, 2H), 3.21–2.93 (m, 6H), 2.20–1.42 (m, 15H), 1.83 (s, 3H), 1.81 (s, 3H), 1.78 (s, 3H), 1,32–1.15 (m, 3H), 0.92 (s, 3H), 0.89 (s, 3H), 0.82 (s, 3H). Signals due to two proton (NH) were not observed; ¹³C NMR (150 MHz, CD₃OD) δ 144.1, 131.6, 126.2, 115.2, 53.8, 51.0, 50.3, 48.0, 47.9, 46.4, 43.1, 40.1, 37.7, 33.9, 33.5, 27.2, 27.1, 26.7, 26.6, 26.0, 24.7, 22.1, 21.8, 19.7, 18.4, 14.1; HRMS (ESI) m/z 389.3902, calcd for $C_{26}H_{49}N_{2}$ [M+H]⁺ 389.3890.


 N^1 -(3-methylbut-2-en-1-yl)- N^8 -(((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methyl)octane-1,8-diamine [**28** (n = 8)]. Yellow solid (8.0 mg, 87% yield): R_f = 0.66 (CHCl₃-MeOH 4 : 1); $[\alpha]_D^{24}$ –9.5 (c 0.68, CHCl₃); IR (CHCl₃) 3398, 2938, 2859, 2773, 1559, 1462, 1382, 1232, 987 cm⁻¹; 1 H NMR (600 MHz, CD₃OD) δ 5.59 (m, 1H), 5.30 (m, 1H), 3.63 (d, J = 7.4 Hz, 2H), 3.21–2.93 (m, 6H), 2.14–2.04 (m, 2H), 1.97–1.35 (m, 17H), 1.83 (s, 3H), 1.80 (s, 3H), 1.78 (s, 3H), 1,32–1.16 (m, 3H), 0.92 (s, 3H), 0.89 (s, 3H), 0.82 (s, 3H). Signals due to two proton (NH) were not observed; 13 C NMR (150 MHz, CD₃OD) δ 144.0, 131.7, 126.2, 115.2, 53.8, 51.0, 50.3, 48.0, 47.7, 46.4, 43.1, 40.0, 37.7, 33.9, 33.5, 29.9 (2C), 27.5, 27.4, 27.3, 26.8, 26.0, 24.7, 22.1, 21.7, 19.7, 18.2, 14.0; HRMS (ESI) m/z 417.4195, calcd for C₂₈H₅₃N₂ [M+H]⁺ 417.4203.




¹H NMR spectra of **11** (400 MHz, CDCl₃)




 ^{13}C NMR spectra of 11 (100 MHz, CDCl₃)




¹H NMR spectra of **12** (400 MHz, CDCl₃)




 13 C NMR spectra of **12** (100 MHz, CDCl₃)




¹H NMR spectra of **6** (400 MHz, CDCl₃)




 13 C NMR spectra of 6 (100 MHz, CDCl₃)




¹H NMR spectra of **13** (400 MHz, CDCl₃)




S21





 ^{1}H NMR spectra of **5** (600 MHz, CDCl₃)




 13 C NMR spectra of **5** (150 MHz, CDCl₃)









 ^{1}H NMR spectra of **18** (600 MHz, CDCl₃)




 13 C NMR spectra of **18** (150 MHz, CDCl₃)




¹H NMR spectra of **19** (600 MHz, CDCl₃)




 ^{13}C NMR spectra of 19 (150 MHz, CDCl₃)




¹H NMR spectra of (+)-halichonine B (2) free amine (600 MHz, CD₃OD)




¹³C NMR spectra of (+)-halichonine B (2) free amine (150 MHz, CD₃OD)




¹H NMR spectra of (+)-halichonine B (2) HCl salt (400 MHz, CD₃OD)




¹³C NMR spectra of (+)-halichonine B (2) HCl salt (100 MHz, CD₃OD)




¹H NMR spectra of **20** (600 MHz, CD₃OD)




 13 C NMR spectra of **20** (150 MHz, CD₃OD)




¹H NMR spectra of **S2a** (600 MHz, CDCl₃)




 13 C NMR spectra of **S2a** (150 MHz, CDCl₃)




¹H NMR spectra of **S2b** (600 MHz, CDCl₃)




 13 C NMR spectra of **S2b** (150 MHz, CDCl₃)




¹H NMR spectra of **S2c** (600 MHz, CDCl₃)




 13 C NMR spectra of **S2c** (150 MHz, CDCl₃)




¹H NMR spectra of **S2d** (600 MHz, CDCl₃)




 ^{13}C NMR spectra of **S2d** (150 MHz, CDCl₃)




¹H NMR spectra of **S4a** (600 MHz, CDCl₃)




 13 C NMR spectra of **S4a** (150 MHz, CDCl₃)




¹H NMR spectra of **S4b** (600 MHz, CDCl₃)




 ^{13}C NMR spectra of **S4b** (150 MHz, CDCl₃)




¹H NMR spectra of **S4c** (600 MHz, CDCl₃)




¹³C NMR spectra of **S4c** (150 MHz, CDCl₃)




¹H NMR spectra of **S4d** (600 MHz, CDCl₃)




 ^{13}C NMR spectra of **S4d** (150 MHz, CDCl₃)




¹H NMR spectra of **S5a** (600 MHz, CDCl₃)




 13 C NMR spectra of **S5a** (150 MHz, CDCl₃)




¹H NMR spectra of **S5b** (600 MHz, CDCl₃)




 ^{13}C NMR spectra of **S5b** (150 MHz, CDCl₃)




¹H NMR spectra of **S5c** (600 MHz, CDCl₃)




 13 C NMR spectra of **S5c** (150 MHz, CDCl₃)




¹H NMR spectra of **S5d** (600 MHz, CDCl₃)




 ^{13}C NMR spectra of **S5d** (150 MHz, CDCl₃)




¹H NMR spectra of **21** (600 MHz, CD₃OD)




¹³C NMR spectra of **21** (150 MHz, CD₃OD)




¹H NMR spectra of **22** (600 MHz, CD₃OD)




 13 C NMR spectra of **22** (150 MHz, CD₃OD)






 13 C NMR spectra of **23** (100 MHz, CD₃OD)




S66




 13 C NMR spectra of **24** (100 MHz, CD₃OD)




¹H NMR spectra of **25** (400 MHz, CD₃OD)




 13 C NMR spectra of **25** (100 MHz, CD₃OD)







 13 C NMR spectra of **26** (100 MHz, CD₃OD)




¹H NMR spectra of **27** (600 MHz, CD₃OD)



 13 C NMR spectra of **27** (150 MHz, CD₃OD)



¹H NMR spectra of **28** (600 MHz, CD₃OD)



¹³C NMR spectra of **28** (150 MHz, CD₃OD)